Oramed Pharma (ORMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 11-2021 | 09-2021 | 08-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,708 | -12,255 | -8,098 | -17,508 | N/A |
| Depreciation Amortization | 11 | 18 | 12 | 69 | N/A |
| Other Working Capital | -2,112 | -699 | -295 | -93 | N/A |
| Other Operating Activity | 3,684 | 1,814 | 1,478 | 3,633 | 0 |
| Operating Cash Flow | $-9,125 | $-11,122 | $-6,903 | $-13,899 | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 7,406 | -100,000 | -99,047 | 4,001 | N/A |
| PPE Investments | -47 | -9 | N/A | -55 | N/A |
| Purchase Of Investment | N/A | N/A | N/A | -25,000 | N/A |
| Other Investing Activity | 0 | 761 | -1 | 0 | 0 |
| Investing Cash Flow | $7,359 | $-99,248 | $-99,048 | $-21,054 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,969 | 60,572 | 60,563 | 96,239 | N/A |
| Other Financing Activity | -677 | 0 | 0 | 1,500 | 0 |
| Financing Cash Flow | $2,292 | $60,572 | $60,563 | $97,739 | $N/A |
| Exchange Rate Effect | -15 | 9 | 23 | -3 | N/A |
| Beginning Cash Position | 27,456 | 77,245 | 77,245 | 21,630 | N/A |
| End Cash Position | 27,967 | 27,456 | 31,880 | 84,413 | N/A |
| Net Cash Flow | $511 | $-49,789 | $-45,365 | $62,783 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,125 | -11,122 | -6,903 | -13,899 | N/A |
| Capital Expenditure | -47 | -9 | N/A | -55 | N/A |
| Free Cash Flow | -9,172 | -11,131 | -6,903 | -13,954 | 0 |